Oppenheimer Trims Price Target on Myriad Genetics (MYGN) After Larger price Cut from Noridian
Tweet Send to a Friend
Oppenheimer trimmed its price target on Perform-rated Myriad Genetics (NASDAQ: MYGN) from $31 to $29 after Noridian, the Medicare contractor ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
